A woman has filed a new Xarelto lawsuit on July 10, 2017, against Janssen Research and Development, Bayer Healthcare, and affiliated companies of both corporations.

Plaintiff Charla W., like many others referenced in multidistrict litigation No. 2592, alleges she experienced Xarelto bleeding side effects, which motivated her to take legal action against the developers and distributors of the drug.

Charla, a resident of the State of Texas, was prescribed Xarelto in March of 2014 to treat and prevent atrial fibrillation. She took the drug for three months prior to her hospitalization in July of the same year.

She spent two days as an inpatient at that time for Xarelto bleeding side effects presenting themselves as severe and recurrent nosebleeds.

The plaintiff in this Xarelto bleeding side effects lawsuit was treated at Northeast Methodist Hospital located in Texas. The drug was determined to be the cause of her nosebleeds, and doctors discontinued her Xarelto regimen.

Xarelto’s History

Xarelto, an anticoagulant medication, was first approved by the Food and Drug Administration in 2011. The first approved use was for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients slated for total joint replacement surgeries involving the knee or hip. The second approved use was for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation such as the plaintiff in this Xarelto bleeding side effects case.

A year later, the anticoagulant was again additionally approved for use in people with a former history of DVT and PE to prevent a recurrent and potentially lethal problem.

According to the factual background section of the legal documentation, the Janssen and Bayer defendants allegedly relied upon studies to promote their anticoagulant product without giving the full story. The studies involved were known as the RECORD, the ROCKET AF, and the EINSTEIN-DVT and PE.

These studies all revealed both the efficacy of Xarelto and a greater tendency for Xarelto bleeding side effects in those taking the drug with a decrease in hemoglobin levels and a tendency to need transfusions. This higher incidence of bleeding events allegedly remained even after researchers accounted for certain patients’ other risk factors for bleeding.

Comparisons were made with a placebo and warfarin, a blood-thinner that had been in use for several decades. This comparison with warfarin continued when advertising and promotion of Xarelto began.

The defendants allegedly mislead the public by suppressing the higher incidence of Xarelto bleeding side effects and talked about how the anticoagulant didn’t need laboratory monitoring or a change of diet–differences that supposedly set it apart from warfarin.

According to the Xarelto lawsuit, Charla suffered pain and anguish and will continue to do so into the future. Because of this, she is bringing counts of negligence, strict products liability, breach of express and implied warranty, fraudulent misrepresentation and concealment, and negligent misrepresentation against the defendants.

She asks for a trial by jury, damages over and above $75,000, reimbursement of all medical, hospital, and medication expenses, all interest occurring prior and post judgement, and assessment of consequential damages.

The Xarelto Bleeding Side Effects Lawsuit is Case No.2:17-cv-06600-EEF-MBN and is part of the Xarelto MDL In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.